See more : ECI Technology Holdings Limited (8013.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Pulmonx Corporation (LUNG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulmonx Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Shanghai Dragon Corporation (600630.SS) Income Statement Analysis – Financial Results
- Spearmint Resources Inc. (SPMT.CN) Income Statement Analysis – Financial Results
- San Neng Group Holdings Co., Ltd. (6671.TW) Income Statement Analysis – Financial Results
- Biotechnologies Assets SA (BST.MC) Income Statement Analysis – Financial Results
- Plymouth Rock Technologies Inc. (PLRTF) Income Statement Analysis – Financial Results
Pulmonx Corporation (LUNG)
About Pulmonx Corporation
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 68.68M | 53.66M | 48.42M | 32.73M | 32.60M | 20.00M |
| Cost of Revenue | 17.92M | 13.80M | 12.79M | 11.53M | 10.18M | 7.72M |
| Gross Profit | 50.75M | 39.87M | 35.63M | 21.20M | 22.41M | 12.29M |
| Gross Profit Ratio | 73.90% | 74.29% | 73.59% | 64.77% | 68.77% | 61.42% |
| Research & Development | 18.08M | 15.40M | 13.06M | 7.46M | 6.05M | 6.99M |
| General & Administrative | 89.81M | 77.01M | 64.77M | 44.57M | 34.20M | 20.35M |
| Selling & Marketing | 4.80M | 6.10M | 5.10M | 1.50M | 600.00K | 100.00K |
| SG&A | 94.61M | 83.11M | 69.87M | 46.07M | 34.20M | 20.35M |
| Other Expenses | 0.00 | -396.00K | -585.00K | 3.28M | -617.00K | -916.00K |
| Operating Expenses | 112.69M | 98.50M | 82.93M | 53.53M | 40.25M | 27.34M |
| Cost & Expenses | 130.61M | 112.30M | 95.72M | 65.07M | 50.43M | 35.06M |
| Interest Income | 5.57M | 1.53M | 400.00K | 213.00K | 432.00K | 21.00K |
| Interest Expense | 3.23M | 1.07M | 829.00K | 3.18M | 2.32M | 2.52M |
| Depreciation & Amortization | 1.95M | 4.00M | 3.16M | 400.00K | 1.20M | 270.00K |
| EBITDA | -55.09M | -55.99M | -46.62M | -28.44M | -16.82M | -15.68M |
| EBITDA Ratio | -80.22% | -107.16% | -98.09% | -88.10% | -54.17% | -78.37% |
| Operating Income | -61.94M | -58.64M | -47.30M | -32.33M | -17.84M | -15.05M |
| Operating Income Ratio | -90.19% | -109.27% | -97.70% | -98.77% | -54.73% | -75.24% |
| Total Other Income/Expenses | 1.66M | 67.00K | -1.01M | 314.00K | -2.50M | -3.42M |
| Income Before Tax | -60.27M | -58.57M | -48.32M | -32.02M | -20.34M | -18.47M |
| Income Before Tax Ratio | -87.76% | -109.15% | -99.80% | -97.82% | -62.40% | -92.32% |
| Income Tax Expense | 571.00K | 353.00K | 343.00K | 213.00K | 363.00K | 12.00K |
| Net Income | -60.84M | -58.92M | -48.66M | -32.23M | -20.70M | -18.48M |
| Net Income Ratio | -88.60% | -109.80% | -100.51% | -98.47% | -63.52% | -92.38% |
| EPS | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| EPS Diluted | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| Weighted Avg Shares Out | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
| Weighted Avg Shares Out (Dil) | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
Pulmonx to Present at Upcoming September Investor Conferences
Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment
Pulmonx Corporation (LUNG) CEO Glen French on Q2 2021 Results - Earnings Call Transcript
Pulmonx Reports Second Quarter 2021 Financial Results
Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Healthcare Delivery Networks
Pulmonx to Report Second Quarter 2021 Financial Results on August 3, 2021
Pulmonx Corporation (LUNG) CEO Glen French on Q1 2021 Results - Earnings Call Transcript
DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls
Pulmonx Corporation (LUNG) CEO Glendon French on Q4 2020 Results - Earnings Call Transcript
Pulmonx to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021
Source: https://incomestatements.info
Category: Stock Reports